公开(公告)号：EP1480976B1

公开(公告)日：2007-09-19

申请号：EP03742945.3

申请日：2003-02-19

申请人： F.HOFFMANN-LA ROCHE AG

发明人： MATTEI, Patrizio ,  NEIDHART, Werner ,  NETTEKOVEN, Matthias, Heinrich ,  PFLIEGER, Philippe ,  TAYLOR, Sven

IPC分类号： C07D417/06 ,  C07D277/42 ,  C07D417/12 ,  C07D417/14 ,  A61K31/425

CPC分类号： C07D417/06 ,  C07D277/42

摘要： Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R5, n, m and A have the significance given in claim 1, can be used in the form of pharmaceutical preparations for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.

公开(公告)号：EP1694673A1

公开(公告)日：2006-08-30

申请号：EP04798115.4

申请日：2004-11-29

申请人： F.HOFFMANN-LA ROCHE AG

发明人： NETTEKOVEN, Matthias, Heinrich ,  ROEVER, Stephan

IPC分类号： C07D417/06 ,  C07D277/56 ,  A61K31/426 ,  A61K31/427 ,  A61P25/32 ,  A61P25/34 ,  A61P3/04

CPC分类号： C07D417/12 ,  C07D277/56 ,  C07D417/06

摘要： The present invention relates to compounds of formula (I)wherein R1, R2, R3 and R4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof, for use as therapeutically active substances. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB 1 receptors.